Search
Lorpiprazole
go.drugbank.com/drugs/DB09195ApprovedLorpiprazole is a serotonin antagonist and reuptake inhibitor used for the treatment of major depressive disorder. It is a piperazinyl-triazole derivative.
Lecanemab
go.drugbank.com/drugs/DB14580ApprovedInvestigational[A253962,L44547] On January 6, 2023, lecanemab was granted accelerated approval by the FDA for the treatment of Alzheimer’s Disease.[L44547] It was granted full FDA approval on July 6, 2023.
Neratinib
go.drugbank.com/drugs/DB11828ApprovedInvestigationalNeratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. … Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer.
Pramipexole
go.drugbank.com/drugs/DB00413ApprovedInvestigationalIt was first approved by the FDA in 1997 [L5882]. … The prevalence of Parkinson's Disease worldwide has increased from approximately 2.5 million in 1990 to about 6.1 million in 2016 [A176861].
Ansuvimab
go.drugbank.com/drugs/DB16385ApprovedInfection with pathogenic filoviruses, such as _Zaire ebolavirus_ (Ebola virus, EBOV), can cause severe hemorrhagic fever in humans, resulting in frequent outbreaks with case fatality rates as high as … However, to date, the most successful method appears to be the development of monoclonal antibodies (mAbs) against the GP<sub>1,2</sub> surface glycoprotein, as evidenced by the previously approved INMAZEB
Etidronic acid
go.drugbank.com/drugs/DB01077ApprovedInvestigational[A203111] Etidronic acid was granted FDA approval on 1 September 1977.[L13901] … [A1923] Etidronate’s use has decreased over the years in favor of the third generation, nitrogen containing bisphosphonate [zoledronic acid], [ibandronic acid], [minodronic acid], and [risedronic acid]
Synonyms: (1-Hydroxyethylidene)bis(phosphonic acid)Products: Didronel Tab 200mg, ETIDRONAT 200MG JENAPHARMCemiplimab
go.drugbank.com/drugs/DB14707ApprovedInvestigational[L39804] Cemiplimab was first approved by the FDA on September 28, 2018, as the first FDA-approved treatment for advanced cutaneous squamous cell carcinoma (CSCC). … [L39804] Cemiplimab was also approved by the European Commission on June 28, 2019.
Amiloxate
go.drugbank.com/drugs/DB11207ApprovedIt is often referred to as isoamyl 4-methoxycinnamate or isoamyl p-methoxycinnamate. Amiloxate is a cinnamic acid derivative with an anti-inflammatory activity [A32916].
Hetacillin
go.drugbank.com/drugs/DB00739ApprovedVet approvedWithdrawnHetacillin has been withdrawn from the market since it has been discovered that it has no therapeutic advantage compared to non-ester derivatives like ampicillin. … Hetacillin has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria.
Duvelisib
go.drugbank.com/drugs/DB11952ApprovedInvestigationalDuvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma … [A39025] Duvelisib was developed by Verastem, Inc and FDA approved on September 24, 2018.[L4585]